These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15752379)

  • 1. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
    J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
    Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
    Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
    Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
    Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
    Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of fraction unbound paclitaxel in human plasma.
    Brouwer E; Verweij J; De Bruijn P; Loos WJ; Pillay M; Buijs D; Sparreboom A
    Drug Metab Dispos; 2000 Oct; 28(10):1141-5. PubMed ID: 10997930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
    Chu Z; Chen JS; Liau CT; Wang HM; Lin YC; Yang MH; Chen PM; Gardner ER; Figg WD; Sparreboom A
    Anticancer Drugs; 2008 Mar; 19(3):275-81. PubMed ID: 18510173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
    Meerum Terwogt J; van Tellingen O; Nannan Panday VR; Huizing MT; Schellens JH; ten Bokkel Huinink WW; Boschma MU; Giaccone G; Veenhof CH; Beijnen JH
    Anticancer Drugs; 2000 Oct; 11(9):687-94. PubMed ID: 11129729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
    Gelderblom H; Loos WJ; Verweij J; van der Burg ME; de Jonge MJ; Brouwer E; Nooter K; Stoter G; Sparreboom A
    Eur J Cancer; 2002 Jan; 38(1):205-13. PubMed ID: 11750851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
    Ellis AG; Webster LK
    Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.